Patient receiving potassium sparing diuretics should be monitoring.

Explanation

Core Concept: Potassium-sparing diuretics such as spironolactone, eplerenone, amiloride, and triamterene reduce urinary potassium excretion. Therefore the major monitoring priority is HYPERKALEMIA, especially in patients with renal impairment, diabetes, heart failure, or concurrent ACE inhibitors, ARBs, NSAIDs, or potassium supplements.

Clinical Presentation: • Muscle weakness, fatigue, paresthesia, nausea, palpitations, decreased reflexes, and potentially life-threatening arrhythmias. • ECG findings may include peaked T waves, widened QRS, prolonged PR, and sine-wave pattern. • Complications include fatal cardiac dysrhythmias and cardiac arrest.

Diagnosis: 1) First-line: serum potassium monitoring and renal function tests. 2) Gold standard/confirmation: repeat serum potassium with clinical correlation; continuous ECG monitoring is required if severe hyperkalemia or ECG changes are present.

Management: Acute - for severe hyperkalemia, administer IV calcium gluconate to stabilize the myocardium, give insulin with glucose, consider inhaled beta-agonist, sodium bicarbonate if acidotic, potassium binders, or dialysis if refractory; stop potassium sources. Definitive/long-term - adjust diuretic therapy, avoid unnecessary potassium supplements, educate about high-potassium foods, and monitor labs regularly.